Park Medi World Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Park Medi World Ltd filed with BSE on 08 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Park Medi World reported Q1 FY27 revenue from operations of Rs.476 crores, up 19% year-on-year, with EBITDA of Rs.126 crores at a 26.5% margin and PAT of Rs.89 crores at an 18.6% margin. The company announced acquisitions of The Medicity Hospital in Rudrapur and Mehar Hospital in Zirakpur, and commissioned the Rudrapur facility on August 2, 2026. Management discussed bed capacity expansion plans reaching 4,740 beds by FY27 end and 5,740 beds by FY28, along with commentary on CGHS rate revisions, payer mix shifts, and case mix trends.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: Rs.476 crores (Q1 FY27)
p. 4
“We reported revenue from operations of Rs.476 crores, year-on-year growth of 19%.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
EBITDA: Rs.126 crores, 26.5% margin (Q1 FY27)
p. 4
“EBITDA, excluding other income, stood at Rs.126 crores, year-on-year growth of 20%, with a margin of 26.5%.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
PAT: Rs.89 crores, 18.6% margin (Q1 FY27)
p. 4
“PAT came in at Rs.89 crores, year-on-year growth of 35%, with a margin of 18.6%.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
Total bed capacity: 3,960 beds (as of 30th June 2026)
p. 4
“Our total bed capacity stood at 3,960-beds as of 30th June, up 32% year-on-year.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
IPD volumes: 26,304 patients (Q1 FY27)
p. 4
“IPD volumes for quarter stood at 26,304 patients, a growth of 16% year-on-year, while OPD volume came in at 2,23,446 patients, up by 17% year-on-year.”
Dr. Sanjay Sharma, page 4 of the filed PDF · View the filing
ARPOB: Rs.30,444 (Q1 FY27)
p. 4
“ARPOB for the quarter was Rs.30,444 compared to Rs.27,221 in Q1 FY’26, an increase of 12% year-on-year, while ALOS improved 8% to 5.9 days from 6.4 days a year ago.”
Dr. Sanjay Sharma, page 4 of the filed PDF · View the filing
Network occupancy: 56% (Q1 FY27)
p. 5
“Network occupancy for the quarter stood at 56% compared to 68% in Q1 FY’26.”
Dr. Sanjay Sharma, page 5 of the filed PDF · View the filing
High-end specialty revenue contribution: approximately 62% (Q1 FY27)
p. 5
“With high-end specialties contributing approximately 62% of the revenue, which is an increase of 440 basis points year-on-year.”
Dr. Sanjay Sharma, page 5 of the filed PDF · View the filing
Term debt: Rs.25.6 crores (as of 30th June 2026)
p. 5
“On the balance sheet, our term debt excluding lease liability stood at Rs.25.6 crores as of 30th June 2026, as against Rs.28.2 crores as of 31, March 2026.”
Rajesh Sharma, page 5 of the filed PDF · View the filing
Net worth: Rs.2,100 crores (as of 30th June 2026)
p. 6
“Our fixed deposit stood at INR300 crores and the net worth at Rs.2,100 crores.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
Payer mix: 77% government insurance, 23% self-pay/private/TPA (Q1 FY27)
p. 6
“Our payer mix for the quarter stood at approximately 77% from government insurance scheme and 23% from self-pay, private insurance and TPA.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
CAPEX per bed: Rs.37 lakhs per bed (Q1 FY27)
p. 6
“The CAPEX per bed remains at Rs.37 lakhs per bed, which continues to be the lowest in the listed healthcare peers.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
Rudrapur acquisition value: approximately Rs.177 crores
p. 3
“we announced a definitive agreement to acquire 100% shareholding in The Medicity Hospital, Rudrapur, Uttarakhand in an all-cash transaction valued at approximately Rs.177 crores, marking our entry into the sixth state.”
Dr. Ankit Gupta, page 3 of the filed PDF · View the filing
Mehar Hospital acquisition value: approximately Rs.107 crores
p. 4
“we announced a definitive agreement to acquire Mehar Hospital, a 150-bedded Multi-Super Speciality Hospital in Zirakpur, serving the wider Tricity catchment, at a valuation of approximately Rs.107 crores.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — Rs.2,080 crores · FY27
stated firmly by Rajesh Sharma
p. 6
“As far as the expected numbers for FY’27 in terms of the revenue, we are expecting a top line of Rs.2,080 crores and with EBITDA of Rs.530 crores and a PAT of Rs.360 crores.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
Revenue growth — 24% · FY27
stated firmly by Rajesh Sharma
p. 6
“So, what we are expecting a growth in compared to last year, revenue growth is 24% and EBITDA growth will be 25% and the PAT growth staggering at 32%.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
Bed capacity — 4,740 beds · end of FY27
stated firmly by Dr. Ankit Gupta
p. 4
“We expect to end financial year 2027 with 4,740 beds, with another 1,000 beds to be added in FY’28.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
Bed capacity — 5,740 beds · FY28
stated firmly by Dr. Ankit Gupta
p. 4
“We will be at 5,740 beds capacity by FY’28, funded largely through internal accruals and IPO proceeds, without recourse to any fresh debts.”
Dr. Ankit Gupta, page 4 of the filed PDF · View the filing
Network occupancy — FY27
stated firmly by Dr. Sanjay Sharma
p. 5
“We expect full-year FY’27 occupancy to moderate from the FY’26 figures of 64%, largely on account of the addition of significant new capacity of 1,490-beds in calendar year 2026.”
Dr. Sanjay Sharma, page 5 of the filed PDF · View the filing
CGHS rate benefit impact — 7% to 7.5% · FY27
stated conditionally by Dr. Sanjay Sharma
p. 5
“On the CGHS rate revision, while we had guided conservatively to a 7% to 7.5% benefit flowing into FY’27, we continue to expect the fuller impact to be visible from Q2 of the financial year as the revised rates percolate through allied central government agencies.”
Dr. Sanjay Sharma, page 5 of the filed PDF · View the filing
Payer mix — 70:30 government to cash/TPA split · next 12-18 months
stated as an aspiration by Rajesh Sharma
p. 6
“Continuing the gradual shift, we have guided towards 70:30 split over the next 12-18 months.”
Rajesh Sharma, page 6 of the filed PDF · View the filing
EBITDA margin — 26%-27% · FY27
stated firmly by Rajesh Sharma
p. 7
“So, we will remain steady on the EBITDA margin of 26%-27% in the current year also.”
Rajesh Sharma, page 7 of the filed PDF · View the filing
ARPOB growth — 10-12% · FY27
stated firmly by Sudesh Sharma
p. 7
“Anshul, broadly speaking, our guidance for ARPOB growth is in a 10-12% band.”
Sudesh Sharma, page 7 of the filed PDF · View the filing
Rudrapur revenue — Rs.100 crores · first year
stated firmly by Dr. Sanjay Sharma
p. 7
“in the first year we feel that we will be able to generate Rs.100 crores of revenue.”
Dr. Sanjay Sharma, page 7 of the filed PDF · View the filing
Rudrapur revenue — Rs.140 crores · second year
stated as an aspiration by Dr. Sanjay Sharma
p. 7
“Next year we feel that we will ramp it up to about Rs.140 crores and the EBITDA will be around Rs.35-36 crores and PAT should be around Rs.21-22 crores.”
Dr. Sanjay Sharma, page 7 of the filed PDF · View the filing
Zirakpur revenue — Rs.70-75 crores with 25-26% EBITDA · FY28 first year of operations
stated as an aspiration by Dr. Sanjay Sharma
p. 8
“we feel that we should be able to generate a revenue of about roughly FY28, Rs.70-75 crores with an EBITDA of about 25-26%.”
Dr. Sanjay Sharma, page 8 of the filed PDF · View the filing
Return on capital — 150-200 basis points increase · next 12-18 months
stated as an aspiration by Sudesh Sharma
p. 10
“We believe that there might be an increase of 150-200 basis points in the next 12-18 months' time.”
Sudesh Sharma, page 10 of the filed PDF · View the filing
CAPEX per bed — Rs.36 lakhs per bed · FY27 and FY28
stated firmly by Rajesh Sharma
p. 12
“that CAPEX will remain at Rs.36 lakhs per bed. We have to see in blended; the blended CAPEX per bed will remain at Rs.36 lakhs.”
Rajesh Sharma, page 12 of the filed PDF · View the filing
Promoter equity dilution — 75% · by December 2028
stated firmly by Sudesh Sharma
p. 12
“You are right, we have a three-year regulatory timeline which lapses in December 2028.”
Sudesh Sharma, page 12 of the filed PDF · View the filing
Payer mix — 70:30 government to cash/TPA · next 12 to 15 months
stated as an aspiration by Rajesh Sharma
p. 16
“Going forward, what we are expecting in the next 12 to 15-months, it will be 70:30.”
Rajesh Sharma, page 16 of the filed PDF · View the filing
ARPOB growth — 10%-12% · two years, annualized
stated firmly by Sudesh Sharma
p. 16
“So, we believe ARPOB guidance going forward is 10%-12% in that band on annualized basis.”
Sudesh Sharma, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management guided to 24% revenue growth and 25% EBITDA growth for FY27, and said newer units will be EBITDA-positive from year one, unlike a slower ramp historically seen at Mohali.
Answered by Rajesh Sharma
Asked by Anshul Agrawal: What is the revenue growth outlook and will EBITDA losses occur at newly commissioned greenfield units like Panchkula?
p. 7
“we are not expecting any loss in these units because ultimately this will give us a revenue of 7, 8 months or 9-months and it will be at least EBITDA-positive in the current year like our Mohali is doing extremely well.”
Rajesh Sharma, page 7 of the filed PDF · View the filing
Management said ARPOB guidance is 10-12% and occupancy will lag due to new bed additions, while mature hospitals are growing steadily.
Answered by Sudesh Sharma
Asked by Anshul Agrawal: Can you split the 24% growth guidance between ARPOB and occupancy?
p. 7
“Anshul, broadly speaking, our guidance for ARPOB growth is in a 10-12% band.”
Sudesh Sharma, page 7 of the filed PDF · View the filing
Management said the CGHS impact has started partially flowing in Q1 with full impact expected by Q2-Q3, and said oncology is not facing pressure from the revision due to strong vendor relationships.
Answered by Dr. Sanjay Sharma
Asked by Kashish Thakur: Has the CGHS rate hike impact started flowing into results, and is oncology facing pressure from the revision?
p. 9
“Yes, the CGHS rate provision has started flowing partially in the Q1 results. And going forward in Q2, Q3 and Q4, we will have the full impact coming up.”
Dr. Sanjay Sharma, page 9 of the filed PDF · View the filing
Management said the 7-7.5% ARPOB impact will largely be reinvested in equipment upgrades and CAPEX rather than flowing directly to EBITDA, while maintaining EBITDA of 26-27% and PAT of 17-18%.
Answered by Dr. Sanjay Sharma
Asked by Sagar Tanna: How much of the CGHS rate hike will flow through to EBITDA?
p. 10
“Yes. But besides that, what I would like to say, we will still be able to maintain the EBITDA between the range of 26% to 27% and PAT between 17% to 18%.”
Dr. Sanjay Sharma, page 10 of the filed PDF · View the filing
Management said expansion has been methodical through densification and new high-potential markets, and expects return on capital to improve by 150-200 basis points over the next 12-18 months.
Answered by Sudesh Sharma
Asked by Nirali Shah: Will incremental economics of new beds diminish as the base expands?
p. 10
“Right now also, we are at around 18%, which is, I believe, one of the best in the listed space hospital sector that we have.”
Sudesh Sharma, page 10 of the filed PDF · View the filing
Management explained the change reflects updated timing of Rudrapur, Palam Vihar and Zirakpur additions rather than any project cancellation.
Answered by Sudesh Sharma
Asked by Shubham Padhiar: Why did the FY27 bed capacity guidance change from 5,040 to 4,740 beds?
p. 11
“No, our communication on expansion plan, which was conservative, has been also consistent in the past.”
Sudesh Sharma, page 11 of the filed PDF · View the filing
Management said on a blended basis CAPEX per bed for FY27-FY28 will remain around Rs.36 lakhs despite Rudrapur being priced higher.
Answered by Rajesh Sharma
Asked by Shubham Padhiar: Will rising CAPEX per bed on recent acquisitions increase payback periods?
p. 12
“that CAPEX will remain at Rs.36 lakhs per bed. We have to see in blended; the blended CAPEX per bed will remain at Rs.36 lakhs.”
Rajesh Sharma, page 12 of the filed PDF · View the filing
Management said it is too early to give an exact timeline, noting they have until December 2028 and will decide based on capital deployment needs.
Answered by Sudesh Sharma
Asked by Shubham Padhiar: What is the timeline for bringing promoter equity down to the 75% listing mandate?
p. 12
“Too early to comment on that. You are right, we have a three-year regulatory timeline which lapses in December 2028.”
Sudesh Sharma, page 12 of the filed PDF · View the filing
Management said the shift toward high-end specialties is organic and driven by market requirements rather than a fixed target.
Answered by Dr. Sanjay Sharma
Asked by Sumit Gupta: What is the target for improving the CONGO (high-end specialty) mix over the next few years?
p. 13
“Sumit, it will be very difficult to actually project or predict any percentage mix in this manner. It is an organic growth.”
Dr. Sanjay Sharma, page 13 of the filed PDF · View the filing
Management guided to a 70:30 government-to-cash/TPA split and ARPOB growth of 10-12% annualized for the next two years.
Answered by Sudesh Sharma
Asked by Ronak Agarwal: What payer mix and ARPOB growth is expected over the next few years?
p. 16
“we believe short-to-mid-term, this number will be having a split of 30:70; 70% patients being beneficiaries of government schemes, therefore 70% of revenue coming from government insurance schemes.”
Sudesh Sharma, page 16 of the filed PDF · View the filing
Risks flagged
New capacity additions entering the occupancy denominator immediately while ramping up over several quarters, pressuring network occupancy
p. 5
“We have added 960-beds across Bhatinda 250, Agra 360, and Panchkula 350, which entered the denominator immediately while ramping up over several quarters.”
Dr. Sanjay Sharma, page 5 of the filed PDF · View the filing
Delay in CGHS rate revision fully percolating through allied government agencies
p. 9
“there are some allied government agencies where the entire impact is yet to percolate, but by Q2, Q3, we should have the entire impact coming in.”
Dr. Sanjay Sharma, page 9 of the filed PDF · View the filing
Some attrition among doctors due to professional or personal reasons
p. 15
“See, little attrition will happen anywhere in this industry because of not reasons, because of professional dissatisfaction, sometimes personal reasons, sometimes extended studies abroad or some fellowship and other reasons.”
Dr. Sanjay Sharma, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.